CandlesenseCandlesense
News/Companies/SLRX

SLRX News

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

SLRX

HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Time, on August 15, 2025. Beginning with the opening of trading on August 18, 2025, Salarius’ common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X503.

August 14, 2025Stock Split
Read more →

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Says A Series Of Antiviral Drug Candidates Previously Designed By Its IMP3ACT Program Showed In Silico Activity Against Measles And Nipah Viruses

SLRX

March 26, 2025
Read more →

Salarius Pharmaceuticals 2024 EPS $(5.79) vs $(30.74) YoY

SLRX

March 24, 2025
Read more →

Salarius Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now up 298.1%

SLRX

January 13, 2025
Read more →

Salarius And Decoy Announces Merger, Decoy To Hold 86% Post-Conversion; Lead Asset To File IND With FDA; Advancements In Broad-Acting Antiviral And Peptide Drug Conjugate; Data Expected From MDACC Trial

SLRX

January 13, 2025
Read more →

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

SLRX

January 13, 2025
Read more →

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

SLRX

January 13, 2025
Read more →